Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06307795 · ClinicalTrials.gov registry record · Phase 1
A Study to Investigate ANS014004 in Participants With Locally Advanced or Metastatic Solid Tumors
A Phase 1 study of Locally Advanced or Metastatic Solid Tumors, sponsored by Avistone Biotechnology Co..
- Recruiting
- Registry status
- Phase 1
- Development phase
- 63
- Enrollment target
- 10
- Study locations
NCT06307795: Recruiting Phase 1 study of Locally Advanced or Metastatic Solid Tumors, sponsored by Avistone Biotechnology Co..
NCT06307795 is a Phase 1 study of Locally Advanced or Metastatic Solid Tumors that is actively recruiting participants, run by Avistone Biotechnology Co.. The registered enrollment target is 63 participants, below the 286-participant average among 5 other Locally Advanced or Metastatic Solid Tumors trials with a reported enrollment target (78% lower). The trial reports 10 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06307795, a Phase 1 study of Locally Advanced or Metastatic Solid Tumors, is actively recruiting participants, sponsored by Avistone Biotechnology Co..
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 63 participants
- Enrollment target
- 10
- Study locations
Study Summary
This is a Phase 1, first-in-human, open-label, multi-center study with the aim of exploring the safety, tolerability, PK, and preliminary anti-tumor activity of ANS014004 as a single agent in participants with locally advanced or metastatic solid tumors.
Primary Outcome
Number of patients with adverse events by system organ class and preferred term
Conditions Studied
Interventions
- DRUG ANS014004
Study Locations (10)
California
- University of California, San Diego - San Diego
Colorado
- Sarah Cannon Research Institute - Denver
Florida
- Advent Health - Orlando
Michigan
- Henry Ford Health Cancer - Detroit
New York
- NYU Langone Health - New York
Texas
- The University of Texas - MD Anderson Cancer Center - Houston
Virginia
- NEXT Oncology, Virginia - Fairfax
Washington
- Swedish Cancer Institute - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 63 participants |
| Start Date | 2024-06-24 |
| Est. Completion | 2027-10 |
| Phase | Phase 1 |
What NCT06307795 shows while recruiting
NCT06307795 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 63 participants, a relatively small participant target, below the 286-participant average among 5 other Locally Advanced or Metastatic Solid Tumors trials with a reported enrollment target (78% lower).
The record links to 1 condition, with Locally Advanced or Metastatic Solid Tumors appearing as the primary indexed condition, and to 1 intervention - of which ANS014004 is the first listed.
NCT06307795 lists 10 locations in 10 states (California, Colorado, Florida).
Frequently Asked Questions
What is clinical trial NCT06307795 about?
NCT06307795 is a clinical study titled "A Study to Investigate ANS014004 in Participants With Locally Advanced or Metastatic Solid Tumors". This is a Phase 1, first-in-human, open-label, multi-center study with the aim of exploring the safety, tolerability, PK, and preliminary anti-tumor activity of ANS014004 as a single agent in participants with locally advanced or metastatic solid tumors.
What is the current status of trial NCT06307795?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 63 participants. The study started on 2024-06-24. Estimated completion is 2027-10.
What conditions does trial NCT06307795 study?
This clinical trial studies the following conditions: Locally Advanced or Metastatic Solid Tumors.
What interventions are being tested in trial NCT06307795?
The interventions under investigation include: ANS014004 (DRUG).
Who is sponsoring clinical trial NCT06307795?
This trial is sponsored by Avistone Biotechnology Co., which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06307795 being conducted?
This trial has 10 study locations across California, Colorado, Florida, Michigan, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Locally Advanced or Metastatic Solid Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
PTT-936 Alone or in Combination in Patients With Locally Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of XB010 in Subjects With Solid Tumors
RECRUITING · Phase 1
-
A Dose-Escalation Study of SPYK04 in Patients With Locally Advanced or Metastatic Solid Tumors (With Expansion).
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03383575 · 63 participants · Phase 2
Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome
- NCT04870944 · 63 participants · Phase 1
CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
- NCT05031897 · 63 participants · Phase 2
Two Step Haplo With Radiation Conditioning
- NCT05312671 · 63 participants · Phase 2
Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI